"Petal-like" size-tunable gold wrapped immunoliposome to enhance tumor deep penetration for multimodal guided two-step strategy

Yanan Li\textsuperscript{a,b}, Wenting Song\textsuperscript{a}, Yumin Hu\textsuperscript{a}, Yun Xia\textsuperscript{a}, Zhen Li\textsuperscript{a}, Yang Lu\textsuperscript{c}, Yan Shen\textsuperscript{a}\textsuperscript{*}

\textsuperscript{a}Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, 210009, P. R. China

\textsuperscript{b}School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, P. R. China

\textsuperscript{c}Laboratory of Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China

\textsuperscript{a}Yanan Li, Wenting Song and Yumin Hu contributed equally to this work

\textsuperscript{*}Corresponding author.

E-mail addresses: Yan Shen, shenyan@cpu.edu.cn; Yang Lu, landocean28@163.com

Abstract

\textbf{Background:} Breast cancer is the fastest-growing cancer among females and the second leading cause of female death. At present, targeted antibodies combined with hyperthermia locally in tumor has been identified as a potential combination therapy to combat tumors. But in fact, the uniformly deep distribution of photosensitizer in tumor sites is still an urgent problem, which limited the clinical application. We reported an HER2-modified thermosensitive liposome (immunoliposome)-assisted complex by reducing gold nanocluster on the surface (GTSL-CYC-HER2) to obtain a new type of bioplasma resonance structured carrier. The HER2 decoration on the surface enhanced targeting to the breast cancer tumor site and forming irregular, dense, "petal-like" shells of gold nanoclusters. Due to the good photothermal conversion ability under near-infrared light (NIR) irradiation, the thermosensitive liposome released the antitumor Chinese traditional medicine, cyclopamine, accompanied with the degradation of gold clusters into 3-5nm nanoparticles which can accelerate renal metabolism of the gold clusters. With the help of cyclopamine to degrade the tumor associated matrix, this size-tunable gold wrapped immunoliposome was more likely to penetrate the deeper layers of the tumor, while the presence of gold nanoparticles makes GTSL-CYC-HER2 multimodal imaging feasible.

\textbf{Results:} The prepared GTSL-CYC-HER2 had a size of 113.5 nm and displayed excellent colloidal
stability, photo-thermal conversion ability and NIR-sensitive drug release. These GTSL-CYC-HER2 were taken up selectively by cancer cells in vitro and accumulated at tumour sites in vivo. As for the in vivo experiments, compared to the other groups, under near-infrared laser irradiation, the temperature of GTSL-CYC-HER2 rises rapidly to the phase transition temperature, and released the cyclopamine locally in the tumor. Then, the released cyclopamine destroyed the stroma of the tumor tissue while killing the tumor cells, which in turn increased the penetration of the liposomes in deep tumor tissues. Moreover, the GTSL-CYC-HER2 enhanced the performance of multimodal computed tomography (CT) and photothermal (PT) imaging and enabled chemo-thermal combination therapy.

**Conclusions:** This optically controlled biodegradable plasmonic resonance structures not only improves the safety of the inorganic carrier application in vivo, but also greatly improves the anti-tumor efficiency through the visibility of in vivo CT and PT imaging, as well as chemotherapy combined with hyperthermia, and provides a synergistic treatment strategy that can broaden the conventional treatment alone.

**Keywords:** plasmon resonance structures, photothermal conversion, cyclopamine, HER2, synergistic, gold nanoparticles.

**Introduction**

Clinically, more than 30% of breast cancer patients overexpressed HER2 protein, which always indicated poor differentiation, rapid proliferation, high distant metastasis rate and poor prognosis[1]. Therefore, HER2 antibody-based monoclonal antibody has been widely used in improving the therapeutic effect of HER2-positive breast cancer patients, gaining great clinical benefit[2]. However, to achieve longer tumor remission period, the clinical regimen also introduced the combination of HER2 antibody monoclonal antibody with chemotherapeutic or photothermal drugs, such as docetaxel, paclitaxel, photosensitizer and other anthraquinone anticancer drugs. Moreover, Her2 antibody-mediated molecular targeted therapy by linking HER2 antibodies with biologically active molecules to form antibody-drug conjugates has also been rapidly developed, which improve the therapeutic index and minimize off-target side effects in normal tissues. Generally, enabling the HER2 antibody to be used in multi-modality therapy and targeted delivery still possesses huge potential.
At present, targeted antibodies combined with hyperthermia locally in tumor has been identified as a potential combination therapy to combat tumors. Recently, gold nanostructures have attracted great interest in the hyperthermia therapy due to their properties such as local surface plasmon resonance (LSPR), photo-thermal transformation efficiency[3-5]. But in fact, the uniformly deep distribution of photosensitizer in tumor sites is still a urgent problem, which limited the clinical application[6]. As we know, after the drug or even nanoparticles reach the tumor site, it stays more in the tumor matrix near the tumor blood vessel, and is difficult to reach the deep area of the tumor to realize the uniform distribution of photosensitizer and total collapse of tumor. The dense extracellular matrix (ECM) in solid tumors is one of the reasons for increasing the solid pressure inside the tumor[7], which hinder the penetration of carrier in tumor tissues. For example, the dense vascular network and the reduction of blood flow limit the convection of NPs, and also extend the diffusion path of NPs from blood vessels to tumor cells. The thickness of fibronectin and collagen in ECM limits the diffusion of NPs[8]. Therefore, many studies are devoted to down-regulating the expression of tumor ECM or selectively degrading the formed ECM[9].

Studies have confirmed[10] that the Hh signal transduction pathway is activated in breast cancer and plays an important role in the occurrence and development of breast cancer. Cyclopamine (CYC) is a traditional Chinese medicine, heterosteroidal alkaloids isolated from plants of the genus Veratrum. It can inhibit the Hh signaling pathway by acting on SMO receptors[7, 11], which in turn can destroy the synthesis of tumor ECM. Jiang T et al[12] showed that the expression of fibronectin in tumor tissues was significantly after CYC treatment. They found significantly improved tumor perfusion and reduced reduced interstitial fluid pressure due to the destruction of the synthesis of tumor ECM. Hence, in addition to act as an anti-tumor Chinese drug, cyclopamine could also help the transport of other drug in tumor tissue and promotes the accumulation and distribution. However, cyclopamine was limited in its clinical application due to poor solubility. Drug delivery vectors, such as liposome, micelle or nanoparticles, are needed to improve the bioavailability of cyclopamine[13].

In our study, two strategies are introduced to achieve deep penetration and the synergistically enhanced antitumor effect for combination therapy. The first step is to construct a plasmon resonance nano-structure that has size-tunable degradability. We firstly grafted the thermosensitive liposome surface with Her2 antibody, which is further decorated with a layer of gold nanoclusters,
forming a biodegradable plasmon resonance structure. Under NIR irradiation, the gold nanoclustered liposome can selectively release gold nanoparticle to realize the size and morphology transformation in the tumor microenvironment through photothermal effect, which could combine the advantages, including the tumor targeting of large particles (\(>100\text{nm}\)) and tumor diffusion of small particles (\(<30\text{nm}\)) for in-depth internal treatment of tumors. Secondly, the chemotherapeutic drug, cyclopamine encapsulated in liposomes could degrade ECM to further improve the diffusion of gold nanoparticles. Besides, liposome also improves the drugability of cyclopamine. Based on above system (Figure 1), gold nanocluster-coated thermosensitive immunoliposome drug delivery system (GTSL-CYC-HER2), it can completely kill the tumor from the outer tumor tissue to deep cores by integrating hyperthermia, chemotherapy and degrading matrix therapy.

Figure 1 Illustration of dual-targeting GTSL-CYC-HER2 and its intracellular trafficking pathway in the tumor cells.

Results and discussion

The grafting ratio of HER2 antibody to thermosensitive liposome
Firstly, the HER2 was investigated to be grafted onto the surface of TSL via amide bond or disulfide bond, respectively. As shown in Table 1, the grafting efficiency by amine bond (86.53%) was much higher than that by disulfide bond (3.33%). It is speculated that both the molecular weight and steric hindrance in space of HER2 antibody is large, which hinder the rapid reaction by disulfide bond. Meanwhile, DSPE-PEG2000-SH is more likely to self-cross-link, resulting in low grafting efficiency with HER2 antibody. Therefore, 1:100 (DSPE-PEG2000-COOH: HER2) was the optimal ratio for amine bond connection, which is used for further experiments. To further confirm the existence and integrity of amine-bound HER2 antibody, the SDS-PAGE electrophoresis was carried out. The results showed that the free HER2 antibody existed two bands at 50kD and 25kD, representing heavy chain CH1 and light chain VH. Then, similar bonds at 50kD and 25kD also appeared in the DSPE-PEG-HER2, TSL-HER2 and TSL-CYC-HER2 sample, indicating that hydrophobic DSPE domain of DSPE-PEG-HER2 had been spontaneously incorporated into the liposome lipid bilaterals (Figure S1).

| Connection method | molar ratio | Added Protein content (μg/mL) | Measured Protein content (μg/mL) | Connection efficiency (%) |
|-------------------|-------------|-------------------------------|----------------------------------|--------------------------|
| Amide bond        | 1:25        | 3.2                           | 0.083                            | 2.60±2.10                |
|                   | 1:50        | 1.6                           | 0.343                            | 21.43±3.44               |
|                   | **1:100**   | **0.8**                       | **0.692**                        | **86.53±6.78**           |
|                   | 1:200       | 0.4                           | 0.316                            | 78.90±6.15               |
|                   | 1:400       | 0.2                           | 0.150                            | 74.84±7.04               |
|                   | 1:25        | 3.2                           | 0.0154                           | 0.48±0.22                |
|                   | 1:50        | 1.6                           | 0.015                           | 0.28±0.13                |
| Disulfide bond    | 1:100       | 0.8                           | 0.004                            | 1.38±1.01                |
|                   | 1:200       | 0.4                           | 0.011                            | 1.94±0.89                |
|                   | **1:400**   | **0.2**                       | **0.008**                        | **3.33±2.33**            |

The characteristics of gold nanocluster-coated thermosensitive immunoliposome drug delivery system (GTSL-CYC-HER2)

As shown in Figure 2A, compared with TSL, the particle size of HER-GTSL did not change
significantly after in situ reduction by chlorauric acid and modification by HER2, due to the electrostatic effect of gold nanoclusters which made the liposome tight. However, attributed to wrapping of gold nanoclusters (GN), the zeta potential of liposomes changed from -25.87±6.15mV to almost electrically neutral. Moreover, the TEM images showed that primary TSL exhibited uniformly smooth surface, while GTSL-CYC-HER2 presented a special "petal-like" structure, which could be explained by the continuous aggregation of gold nanoclusters on the surface of liposomes, forming irregular petal-like shells of gold nanoclusters on the surface of liposomes (Figure 2A). We found the coating level of GN on TSL was controlled by the concentrations of the GN precursors (Figure S2). When 24μl of HAuCl₄ and 36μl of ascorbic acid was mixed with 1ml TSL, the special thickness of GN could turn the UV absorption wavelength from 600nm to 800nm, which is suitable for the deep penetration of light [14](Table S1).

To further determine the binding of GN on TSL, energy dispersive X-ray spectroscopy was used to detect the element peak of Au. Different from the TSL, the results indicated that an obvious Au peak appeared in the EDS spectrum of GTSL (Figure 2B). It is noted the position of Au and P in phospholipids was similar, indicating the co-localization of phospholipids and gold phosphorus. Therefore, the gold nanoclusters were successfully modified on the surface of liposomes. Furthermore, UV−vis absorption spectra demonstrated that GTSL and GTSL-HER2 displayed distinct absorption peak at 819 nm and 840 nm, respectively (Figure 2C), which confirmed the excellent localized surface plasmon resonance (LSPR). Thus, the photo-electronic converting property of the GTSL-CYC-HER2 was explored. As shown in Figure 2D&E, the extraordinary photothermal performance of GTSL, GTSL-CYC, GTSL-HER2, GTSL-CYC-HER2 was confirmed as the solution temperature rose rapidly from 22°C to 40.5°C, 39.2°C, 40.2°C and 38.9°C within 10 min, respectively, while a barely photothermal effect was observed in PBS and TSL groups. Moreover, the loading of CYC inside GTSL cause no effect on the LSPR properties of GN. Besides, the photothermal effect of GTST and GTSL-CYC keep stable in a 5-cycle irradiation study, only witnessing a slight decay in the fifth photothermal conversion compared with the first irradiation (Figure 2F&G). This observation indicated that the TSL could greatly conserve the photothermal conversion efficiency of GN. Further, with the continuous repeat of irradiation times, the GN on the surface of TSL will be broken into small gold nanoparticles, which reduced the
photothermal conversion ability. However, the small particles could be easily cleared by kidney metabolism with less accumulated toxicity *in vivo*. Finally, after drawing the linear relation between the cooling time and \(-\ln \theta\) (Figure S3), the photothermal conversion efficiency of GTSL and GTSL-CYC-HER2 were calculated by the formula as 30.14% and 37.96% respectively (Table S2). This result was higher than the reported photothermal materials[15], including the gold nanorods (~21%), gold nanoparticles (~11%), MoS2 nanoplates (~27.6%) and Bi nanoparticles (~30%). Considering the TSL encapsulated in the GN, the GTSL can be regarded as a hollow gold nanostructure with a larger kernel size. Hence, the photothermal conversion efficiency was higher under NIR irradiation as the specific surface area is much larger than that of other photothermal materials.
Figure 2 (A) Representative TEM images of TSL (left), TEM images (medium) and SEM images (right) of GTSL-HER2. (Scale bar: 100 nm) (B) The EDS spectrum of TSL and GTSL. (C) The UV–vis absorption spectra of GTSL and GTSL-HER2. (D) The photothermal image of GTSL, GTSL-CYC, GTSL-HER2, GTSL-CYC-HER2. (E) Temperature change of PBS, TSL, GTSL, GTSL-CYC, GTSL-HER2 and GTSL-CYC-HER2. Temperature increments of GTSL, GTSL-CYC (F) and GTSL-HER2, GTSL-CYC-HER2 (G) after 5 repeated irradiations (black arrow indicates temperature before illumination and red arrow indicates temperature after illumination).

The photothermal responsive release behavior and degradation of GTSL-CYC-HER2
We next examined the photothermal responsive release behavior of GTSL-CYC-HER2 triggered by manually controlled NIR irradiation in simulated different humoral conditions in vitro. Firstly, all the liposome preparations showed a sustained release in pH 7.4 compared with free CYC (4h, 69.61%) (Figure 3A&B). Among that, TSL-CYC, TSL-CYC@NIR, TSL-CYC-HER2, TSL-CYC-HER2@NIR, GTSL-CYC and GTSL-CYC-HER2 achieved 36.75%, 39.81%, 39.04%, 41.57%, 39.93 % and 36.33 % release within 48h, while GTSL-CYC@NIR and GTSL-CYC-HER2@NIR reached 64.20% and 68.44% in 48h, suggesting that the manually controlled NIR irradiation could accelerate the release of encapsulated CYC in the TSL (Figure 3A&B). It is noted the cumulative release of CYC in the first 2h appeared a burst release with 56.86% and 54.18% in GTSL-CYC@NIR and GTSL-CYC-HER2@NIR groups. The above results indicated that GTSL-CYC-HER2 could effectively convert light energy into heat and the temperature reached phase transition temperature under 808nm NIR irradiation, which promoted the release of CYC from TSL. Next, to observe the release behavior in the lysosome, the PBS at pH5.4 was chosen as the release medium. As shown in Figure 3C&D, the release profile indicated that there was 57.02%, 51.09%, 61.58% and 63.99% of CYC liberated from TSL-CYC, TSL-CYC@NIR, TSL-CYC-HER2 and TSL-CYC-HER2@NIR groups at 48h, suggesting a faster release effect in lysosome. The cumulative release in 48h was 94.15% for GTSL-CYC and 98.85% for GTSL-CYC-HER2 in lysosome under the laser irradiation. Attributed to the acidic lysosomal environment, the stability of TSL was further reduced and CYC almost completely released.

To further observe the degradation of GTSL-CYC-HER2, the morphology of the particles under different conditions was recorded. Clearly, the GTSL-CYC-HER2 presented "petal-like" with a clean background without laser irradiation (Figure 3E). However, after irradiation, the "petal-like" structure turned into spherical shape. It is speculated when the temperature rose rapidly to the phase transition temperature accompanied with unstable lipid membrane, the gold nanoclusters on the surface gradually turned into free small gold nanoparticles of 5-8nm. Furthermore, the degradation experiment was also performed in simulated humoral conditions (blood solution and lysosome solution). From Figure 3F, we can see that GTSL-CYC-HER2 degraded gradually in neutral SBF solution. From 0h to 24h, the GM mostly separated from the TSL-HER2 while the liposome still kept the spherical structure. But from 24h to 48h, all the GN completely liberated from the TSL and
the liposome mostly broke apart to release CYC. However, the GTSL-CYC-HER2 began to appear as an unstable precipitate within 24h in SLF solution becoming the free GNs and broken liposome fragments. The degradation rate was sharply faster than that in SBF solution due to the enhanced β-ester hydrolysis of phospholipids in the acid environment, indicating the good biocompatibility. Therefore, the gold nanoclusters not only prolonged their biodegradation rate by stabilizing the liposome core, but also were metabolized to 5-8nm particles to be cleared by kidneys. This controllable and biodegradable complex provided a great platform for synergistic treatment of photothermal therapy and chemotherapy.
Figure 3 In vitro release of free CYC, TSL-CYC, GTSL-CYC and free CYC, TSL-CYC-HER2 and GTSL-CYC-HER2 with or without NIR in pH 7.4 (A-B) and in pH 5.4 (C-D) (*p<0.05, **p<0.01).

(E) Degradation behaviors of GTSL-CYC-HER2 irritated without or with NIR. (red arrows indicate gold nanoclusters, black arrows indicate free gold nanoseeds)

(F) Degradation behaviors of GTSL-CYC-HER2 in SBF (a-c) and SLF (d-f) observed by TEM at 0h, 24h, 48h. (Red arrows indicate liposome fragments) (a-d: Scale bar=100 nm. e-f: Scale bar=50 nm).
The in vitro cellular evaluation of GTSL-CYC-HER2 at cellular level

We first evaluated the expression of HER2 protein among four different cancer cells by western blot and immunofluorescence methods, including MCF-7, MDA-MB-453, BT474 and SK-BR-3 cells. According the expression content (Table S3 and Figure S4), MCF-7 was chosen as the low-expression cell and SK-BR-3 as the high-expression cell of HER-2 for further cellular evaluation experiments. In addition, the single irradiation with power of 1 or 3 w/cm² had no significant effect on the viability of cells while the power of 5 w/cm² caused 10-15% mortality (Figure S5). Considering the photothermal effect and safety, 3 w/cm² was chosen as the optimal irradiation power for further experiments.

The cytotoxicity was tested by MTT assay to evaluate the synergistic therapeutic effect on MCF-7 and SK-BR-3 cells. Firstly, in MCF-7 cells, there was almost no significant difference between the synergic treatment group and single therapy groups at the low concentration of 0.5mg/ml (Figure 4A&B). This finding was ascribed to the low content of CYC and GNs in the TSL which as unable to produce effective chemotherapeutic response and photothermal conversion ability. With the increase of liposome concentration, both the CYC inside TSL and GNs on the TSL concentration increased, the advantages of synergistic therapy began to emerge. The inhibitory effects of GTSL-CYC-HER2@NIR on MCF-7 cells were significantly higher than those of the single chemotherapy group and the single photothermal group (**p<0.01). When the liposome concentration reached 5mg/mL, the average inhibition percent of GTSL-CYC-HER2@NIR were 68.65% and 70.67%, respectively, which were much higher than the average inhibition percent of GTSL-CYC (49.67%) and GTSL-CYC-HER2 (51.05%), respectively(***p<0.001). It was also much higher than that for GTSL@NIR (49.59%) and GTSL-HER2@NIR (51.69%)(***p<0.001) (Figure 4A&B). All the above results indicated that the synergistic photothermal and chemotherapy could significantly inhibit the proliferation of MCF-7 cells. Next, compusyn software was introduced to calculate the synergistic treatment index, shown in Table S4. Generally, the synergistic index CI is basically less than 1, which confirmed the synergistic “1+1 > 2” effect of chemotherapy combined with hypertermia for GTSL-CYC-HER2, instead of a simple superposition effect. With liposome concentration increasing, CI further declined, demonstrating an enhanced synergy (Figure S6). Besides, similar results were obtained with SK-BR-3 cells (Figure 4C&D and Figure S7). However,
it is noted that HER2-decorated GTSL-CYC-HER2@NIR exhibited superior higher killing ability than GTSL-CYC@NIR in SK-BR-3 cells, which is attributed to the high expression of HER2 and enhanced targeting (Table S5).

The targeting evaluation of GTSL-CYC-HER2 in vitro

Next, we further investigated the cellular uptake behavior of GTSL-CYC-HER2@NIR determined by fluorescence inverted microscope and flow cytometry. As shown in Figure 4E, during 6h incubation, the increasingly accumulated fluorescence was detected in MCF-7 cells, revealing the time-dependent uptake. At the same time point, the fluorescence of TSL-C6-HER2 is similar with that of TSL-C6, suggesting the HER2 coating could not enhance the uptake by MCF-7 cells. However, the significant difference of fluorescence appeared between the TSL-C6 and TSL-C6-HER2 groups in SK-BR-3 cells (Figure 4E&F&G). We further confirmed the HER2-mediated active uptake by receptor saturation inhibition assay. After saturation by excessive HER2 solution, the uptake of GTSL-CYC-HER2 dramatically reduced with 6h in SK-BR-3 cells (Figure 5H). All the results demonstrated that GTSL-CYC-HER2 could be effectively transferred into HER2-expressing tumor cells.

Finally, to test the uptake ability of gold element by tumor cells, the Au/protein at different point was detected via ICP-MS. In MCF-7 cells, the laser irradiation was able to improve the uptake of Au by MCF-7 cells (Figure S8A). This phenomenon may be due to that heat generated by laser excitation can promote the fluidity of cell membrane and thus improve the uptake of GNS[16, 17]. Furthermore, the free GNs separated from TSL were more favorable for endocytosis process with smaller size[18, 19]. The same trend was found in the uptake assay in SK-BR-3 cells. Different from that in MCF-7 cells, a significantly increased uptake rate of Au was observed in GTSL-CYC-HER2(**p<0.001) (Figure S8B&C), compared with that in GTSL-CYC, which further indicated the active targeting to HER2-positive cells.
Figure 4 MCF-7 Cell viability of the synergy group compared with the chemotherapy groups (A) and hyperthermia groups (B). (\*\*p<0.01, \*\*\*p<0.001). SK-BR-3 Cell viability of the synergy group compared with the chemotherapy groups (C) and hyperthermia groups (D). (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001) (E) MCF-7 cell uptake of TSL-C6 and TSL-C6-HER2 and SK-BR-3 cell uptake of
TSL-C6 and TSL-C6-HER2 (Scale bar=50 μm). Mean fluorescence intensity of TSL-C6 and TSL-C6-HER2 in SK-BR-3 cells (F) and MCF-7 cells(G) (*p<0.05, **p<0.01, ***p<0.001). (H) Quantitative comparison of GTS-CYC-HER2@NIR uptaken into SK-BR-3 cells with or without HER2 antibody blocking (**p<0.01).

In vivo targeting and antitumor efficacy

It is reported that HER-2-decorated liposome can target to tumor sites owing to the passive EPR effect and active receptor-mediated endocytosis effect. The targeting ability of GTSL-CYC-HER2 was firstly verified by in vivo imaging system by labeling TSL with Dir. As presented in Figure 5A&B&C, after intravenously injecting Dir@GTSL-HER2, the increased accumulated Dir fluorescence was detected in tumor area within 24h, while the fluorescence of free Dir group suffered from a rapid decline. Fluorescence images of all organs at 24h further showed the fluorescence of the GTSL-HER2 group was 1.5 times that of the GTSL group and five times that of the free Dir group, suggesting the longer retention time of GTSL-HER2 in the tumor site. These results clarified that GTSL-HER2 could actively target to tumor area and be delayed in tumor. Besides, it is noted the liposome preparations also tended to be accumulated in the liver and kidneys, compared with free Dir group. This phenomenon may be due to the enrichment of blood vessels in these metabolic organs, which is consistent with the reported results[20]. Based on the superior targeting ability, the localized photothermal property in tumor was determined by near infrared photothermal imaging technology after intravenously injection of different preparations for 24 h. Compared to the unobvious temperature increase in the saline group and GTSL group, the tumor temperature in mice treated with GTSL-HER2 quickly reached up to 45°C with 5min of laser irradiation (3W/cm²), indicating the superior photothermal conversion ability(**p<0.01) (Figure 5D&E). In addition, the photothermal imaging caused by NIR can also monitor the treatment process in real time, which provides new platform for the evaluation of therapeutic efficacy.

Compared with iodine, gold has a higher atomic number, indicating strong X-ray attenuation ability and great potential in CT imaging. Herein, we also established in situ breast cancer model to verify the tumor-targeted CT imaging ability. After intravenously injection of different preparations,
Figure 5F&G showed that the brightness of the tumor site did not change significantly with the extension of time in iodothyol solution group. However, the obvious brightness appeared in the bladder after 2h and then disappeared fastly, indicating that iodothyol was easy to be metabolized and cleared in vivo. Excitingly, the tumor site in mice treated with GTSL and GTSL-HER2 evidenced an enhanced contrast effect at both 2h and 8h. And the intensity of GTSL-HER2 was significantly higher than that of GTSL, suggesting the GTSL-HER2 possessing better targeted contrast effect. Next, we determined the content of Au in the organs and found that although Au element was mostly accumulated in the liver and spleen, the Au content of GTSL-HER2 was obviously more than that in other groups, clarifying the targeted CT imaging potential.

Above results all demonstrated the good targeting ability and excellent photothermal performance. Then, we evaluated the antitumor effect in the in situ breast cancer-bearing mice. Figure 6A&B showed that NIR group exhibited negligible tumor suppression after treatment for 14 days. In addition, the single therapy, such as GTSL@NIR or CYC group, only showed modest antitumor effect, which revealed the limitation of single therapy. However, compared to GTSL-CYC, the tumor in GTSL-CYC-HER2 group was further inhibited, which could be attributed to the enhanced active targeting with HER2 decoration. Moreover, significant tumor ablation was observed in the combined treatment group, especially GTSL-CYC-HER2@NIR group. This amplified antitumor effect was due to the following reasons. Firstly, under near-infrared laser irradiation, the temperature of GTSL-CYC-HER2 rises rapidly to the phase transition temperature, and released the cyclopamine locally in the tumor. Then, the released cyclopamine destroyed the stroma of the tumor tissue while killing the tumor cells, which in turn increased the penetration of the liposomes in deep tumor tissues. This strategy accelerated the process of tumor collapse just like peeling the onion layer by layer. Moreover, the weight of mice in all groups kept stable without significant difference, and all organs showed no obvious injury, suggesting potentially good biosafety during therapy in vivo (Figure S9& S10). Finally, Hematoxylin and eosin (H&E) staining of tumor tissue showed much more severe tumor cell damage in GTSL-CYC-HER2@NIR group, because of the obvious cell shrinkage and nuclear condensation (Figure 6C). Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay further indicated the most obvious tumor cell apoptosis of tumor cells in GTSL-CYC-HER2@NIR group (Figure 6D). These
results clearly proved the enhanced synergistic therapeutic effect by integrating the photothermal therapy, chemotherapy and disruption of tumor stroma.

Figure 5(A) The *in vivo* imaging of SK-BR-3 tumor bearing mice after intravenous injection of free
Dir, Dir loaded GTSL, and GTSL-HER2. (Red circles represent the tumor site). (B) The images of ex vivo organ of mice at 24 h after injection free Dir, Dir loaded GTSL, and GTSL-HER2. (C) The average fluorescence intensity of ex vivo organs and tumors of mice at 24 h after injection of different groups (n = 3, mean ± SD). (*p<0.05, ***p<0.001). (D) In vivo photothermal imaging with a NIR laser at 0, 1, 3 and 5 min of SK-BR-3 tumor-bearing mice 24h after intravenous injection of saline, GTSL and GTSL-HER2. (Green circles represent the tumor site). (E) Temperature changes of the SK-BR-3 tumor-bearing mice during NIR irradiation at different points of different groups (n = 3, mean ± SD). (**p<0.01). (F) The in vivo CT imaging of SK-BR-3 tumor bearing mice after intravenous injection of PBS, Iohexol, GTSL, and GTSL-HER2. (Red circles represent the tumor site). (G) The average Au amount of ex vivo organs and tumors of mice at 8 h After injection of different groups (n = 3, mean ± SD). (**p<0.01).
Figure 6 (A) The tumor images of different treatment groups at 14 day treatment. (B) Tumor volume changes in different treatment groups within 14 days. groups (n =5, mean ± SD). (*p<0.05, **p<0.01, ***p<0.001). (C) Representative H&E staining images of tumor tissues after different treatments (Scale bar=100 μm). (D) TUNEL images of tumor tissues after different treatments (Scale bar=100 μm).

Conclusion

In summary, a gold nanocluster-coated thermosensitive immunoliposome drug delivery system by integrating the adjustment of particle size and tumor stromal collapse strategies was developed
for deep and thorough tumor ablation. In our study, HER2 modification could enhance the active targeting to tumor to a great extent. Different from the photothermal property of single AuNPs, the gold nanocluster on the surface of TSL exhibited superior photothermal converting ability because of the large cavity structure. Subsequently, photothermal effect triggered the decreasement of particle size and release of cyclopamine which further enhance the penetration of this preparations, achieving a synergistic “1+1>2” effect. Ultimately, the cell and animal experiments convincingly illustrated that the GTSL-CYC-HER2@NIR had promising antitumor effect and lower side effects. The GTSL-CYC-HER2 presented here provided a promising delivery platform that realizes the controllable combination of different therapies.

**Materials and experiment methods**

**The synthesis and characterization of Her2-lipid**

To optimize connection efficiency of phospholipids and antibodies, two reaction strategies (amide bonds [21] and disulfide bonds[22]) were carried out referring to reports[23]. In the experiment, the molar ratios of DSPE-PEG2000-COOH and DSPE-PEG2000-SH to HER2 were 1:25, 1:50, 1:10, 1:200, 1:400 respectively. After reaction, the DSPE-PEG2000-HER2 was purified by column chromatography. The connection rate was calculated by the following formula. Besides, free HER2, DSPE-PEG-HER2 was examined by SDS-PAGE to confirm its molecular weight.

\[
\text{Connection rate}(\%) = \frac{C_1}{C_0} \times 100\%
\]

**Preparation of gold nanocluster-coated and cyclopamine-loaded thermosensitive immunoliposome(GTSL-CYC-HER2)**

According to the following figure 7, the thermosensitive liposome (TSL) and CYC-loaded TSL (TSL-CYC) were prepared by thin film dispersion method. Then, the DSPE-PEG2000-HER2 was added into above liposome solution to incubate for about 18h at 4°C (DSPE-PEG2000 to DSPE-PEG2000-HER2=1:1). Finally, the HER2 modified liposome formed after removing the free HER2 antibody with CL-4B agarose gel column.
Next, 24 μl HAuCl₄ (100nM) was added into TSL-HER2 solution and mixed uniformly. Then the reducing agent ascorbic acid (36μl, 500nM) was added into above solution and shake gently until the color of solution changes from transparent white to dark blue or dark green, suggesting that GTSL, GTSL-HER2 and GTSL-CYC-HER2 were formed.

Figure 7 Preparation of drug-loaded thermosensitive immunoliposomes coated with gold nanoclusters

**Characteristics of GTSL-CYC-HER2**

**Size and zeta potential detection**

The prepared TSL-HER2 and GTSL-CYC-HER2 were diluted to a concentration of 1mg/mL, and then the particle size and zeta potential were determined by laser particle size analyzer (Brookhaven Instruments, USA).

**TEM imaging**

Drop the TSL-CYC and GTSL-CYC-HER2 solution on the copper net covered with carbon film for 30s, respectively. The absorb the excess liquid with filter paper and dry it for about 3min under the light. The morphology of the preparations was observed by transmission electron microscope and scanning electron microscope.
Energy dispersive X-ray spectroscopy

Add 3% sucrose as a freeze-dried protective agent to an appropriate amount of TSL and GTSL solution. Then the surface binding of gold nanoclusters and phospholipids was analyzed by energy dispersive X-ray spectroscopy (EDS).

Ultraviolet spectrum scanning

The GTSL and GTSL-HER2 solutions were diluted to a concentration of 1 mg/mL. And the solution was scanned with an ultraviolet-visible spectrophotometer in the range of 400-1000nm.

The temperature change after laser irradiation

Continuous laser irradiation

GTSL, GTSL-CYC, GTSL-HER2, GTSL-CYC-HER2 were diluted to 10mg/ml and was irradiated (3W/cm²) for 10min, PBS and TSL as controls. After 10 minutes of continuous laser irradiation with a power of 3W/cm², an infrared thermal imager was recorded to monitor the temperature change in real time, and to investigate photothermal converting ability under NIR irradiation. In addition,

Pulsed laser irradiation

The solutions of GTSL, GTSL-CYC, GTSL-HER2 and GTSL-CYC-HER2 were diluted to 10mg/mL and irradiated with NIR irradiation (3W/cm²) respectively. The temperature of the solution was recorded by continuous irradiation for 10 min. After the temperature returned to the initial temperature, the above circular irradiation was repeated for five times. The the temperature changes in each irradiation period were recorded with an infrared thermal imaging instrument to investigate the photothermal effect of gold nanoclusters on the surface of TSL.

Calculation of photothermal conversion efficiency

The preparations were diluted to 1mg/ml and placed in a colorimetric dish to weigh the mass of the sample (m). The samples above were measured at 808nm for their ultraviolet absorbance value (A), and then were irradiated with an 808nm laser (3W/cm²) for 540s, followed with natural cooling time of 540s. The temperature changes were recorded by an infrared thermal imager every 30s, purified water as a blank control. The photothermal conversion efficiency (η) is calculated by the following formula[24]:

\[ \eta = \frac{A_{s} - A_{b}}{A_{s}} \times 100\% \]
\[ \theta = \frac{T - T_{\text{surr}}}{T_{\text{max}} - T_{\text{surr}}} \]
\[ k = -\ln \theta / T \]
\[ hS = \frac{mc_{\text{water}}}{k} \]
\[ Q_{\text{dis}} = \frac{mc_{\text{water}}(T_{\text{max}}(\text{water}) - T_{\text{surr}})}{k_{\text{water}}} \]
\[ \eta = \frac{hS(T_{\text{max}} - T_{\text{surr}}) - Q_{\text{dis}}}{\ln 10^{A}} \]

Where H is the heat transfer coefficient, S is the surface area of the container, \( T_{\text{max}} \) is the highest temperature at which the sample solution is heated up, \( T_{\text{surr}} \) is the ambient temperature at which the sample is tested, I is the power density of the laser, and A is the absorption intensity of the sample at 808nm. M is the mass of the sample solution, and \( C_{\text{water}} \) is the specific heat capacity of water. In order to calculate \( hS \), \( \theta \) is introduced in this experiment to define \( k \), that \( k \) is the slope of the line (t-\(-\ln\theta\)). In the formula, \( Q_{\text{dis}} \) is the value of blank sample, and \( T_{\text{max}}(\text{water}) \) is the maximum temperature of water after the illumination. \( k_{\text{water}} \) represented the slope between \(-\ln\theta\) of water and irradiation time.

The analysis of release behavior

The PBS solution containing 20% PEG was prepared as release medium and was adjusted to pH 7.4 and pH 5.4 to simulate normal blood environment and lysosome environment. 0.8ml of CYC, TSL-CYC, GTSL-CYC, TSL-CYC@NIR, GTSL-CYC@NIR, TSL-CYC-HER2, GTSL-CYC-HER2, TSL-CYC-HER2@NIR and GTSL-CYC-HER2@NIR solution were placed in the dialysis bag, respectively. Then the dialysis bags were immersed in a centrifuge tube containing 8 mL of release medium and shake with the speed of 100rpm at 37°C. Among that, the laser irradiation group TSL-CYC@NIR, GTSL-CYC@NIR, TSL-CYC-HER2@NIR and GTSL-CYC-HER2@NIR were taken out of the centrifuge tube at specific points (0, 2, 4, 6h) , to give a continuous irradiation for 5 minutes, and then put it back into the centrifuge tube. All the above samples were taken 0.1ml of releasing medium for further detection and replace it with fresh medium at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48h, respectively. The CYC in the samples was detected by HPLC, which was performed on RP-18 column (Zorbax Eclipse Plus, 5 μm, 250 mm×4.6 mm, Agiligent) , mobile phase was methanol-ammonium acetate (0.05M) (70:30); and the detection wavelength was set at 210 nm, the
flow rate was 1 Ml/min, the column temperature was set at 25℃, and the sample size was 20 μL, after determination the cumulative release curve was plotted.

The degradation behavior of GTSL-CYC-HER2

The degradation of GTSL-CYC-HER2 after laser irradiation

The GTSL-CYC-HER2 was irradiated with the NIR laser with a power of 3.0 W/cm². After continuous irradiation for 10 minutes, the morphology and particle size of GTSL-CYC-HER2 before and after the irradiation were observed with a transmission electron microscope for comparison.

Degradation of GTSL-CYC-HER2 in simulated body fluids and simulated lysosomal environments

Na₂HPO₄ 142.0mg, NaCl 6.65g, Na₂SO₄ 71mg, CaCl₂·2H₂O 29mg, glycine 450mg, potassium hydrogen phthalate 4.084g and benzalkonium chloride 50mg were dissolved in 1L water as SLF solution to stimulate lysosome environment. Each 1mL of GTSL-CYC-HER2 was placed in 10mL of simulated body fluid (SBF, pH 7.4) and SLF (pH 4.0), respectively. After co-incubated in a shaker of 180rpm at 42℃ for 48h, the morphology and particle size of GTSL-CYC-HER2 were observed by TEM at 0h, 24h and 48h respectively.

The evaluation on cell level

The expression of HER2 on various breast tumor cells

In this study, the expression of HER2 were determined by Western blot method and Immunofluorescence method in MCF-7, MDA-MB-453, BT474 and SK-BR-3 cells. Based on the expression content, low-expressing and high-expressing cells were screened for further study.

The cytotoxicity assay in MCF-7 and SK-BR-3 cells

The cells were seeded in a 96-well plate at a density of 10,000 per well. After 24h incubation, the following preparations diluted in different concentrations were added respectively, including TSL-CYC, GTSL-CYC, GTSL-CYC-HER2, TSL@NIR, GTSL@NIR, GTSL-HER2@NIR, TSL-CYC@NIR, GTSL-CYC@NIR, GTSL-CYC-HER2@NIR, the zero hole and PBS as blank control groups. Among that, TSL@NIR, GTSL@NIR, GTSL-HER2@NIR, TSL-CYC@NIR, GTSL-
CYC@NIR, GTSL-CYC-HER2@NIR was firstly placed in the incubation for 4h, and then was irradiated for 5min with 808nm laser (3.0 W/cm²). After the irradiation, put it in the incubation and continue culture, similar with other group. With other 20h incubation, 10 μL of 0.5% MTT solution was added to each well and continue culturing for 4 hours. Finally, the solution in the holes was removed and washed with PBS for three times, followed with addition of 150μL of DMSO to solve the crystal. The absorbance of each well was determined by enzyme-labeled instrument at the OD 570nm. The cell viability could be calculated according to formula

\[
\text{Cell viability \%} = \frac{(A_{\text{sample}} - A_{\text{blank}})}{(A_{\text{control}} - A_{\text{blank}})} \times 100\
\]

Where, \(A_{\text{sample}}\) represents absorbance value of the sample while \(A_{\text{blank}}\) represented the absorbance value of zero hole. \(A_{\text{control}}\) is the absorbance value of the control hole.

**Study on synergistic index of chemotherapy combined with hyperthermia**

The synergistic effects of chemotherapy and hyperthermia were studied via Compusyn software. According to the report of Chou and Talalay, the Combination Index (CI) was used as the Index to evaluate the synergistic effect[25]. As shown in Table 2, this standard was used to determine whether GTSL-CYC@NIR had synergistic effects in MCF-7 cells and SK-BR-3 cells.

| Range of Combination Index | Description               |
|----------------------------|---------------------------|
| <0.1                       | Very strong synergism     |
| 0.1–0.3                    | Strong synergism          |
| 0.3–0.7                    | Synergism                 |
| 0.7–0.85                   | Moderate synergism        |
| 0.85–0.90                  | Slight synergism          |
| 0.90–1.10                  | Nearly additive           |
| 1.10–1.20                  | Slight antagonism         |
| 1.20–1.45                  | Moderate antagonism       |
| 1.45–3.3                   | Antagonism                |

**Cell uptake study of GTSL-CYC-HER2 on tumor cells**
The TSL-C6 and TSL-C6-HER2 loading fluorescein C6 were prepared by the thin film dispersion method. The MCF-7 cells and SK-BR-3 cells were seeded in 6-well plates. After 24h incubation, the medium was removed and the free C6, TSL-C6 and TSL-C6-HER2 prepared were added with the concentration of C6 of 100ng/ml. At 2h, 4h, and 6h, the holes were washed three times with PBS, and were placed under an inverted fluorescence microscope to observe the uptake content. In addition, the above experiment was repeated. At 2h, 4h, and 6h, the cells in hole were all collected and re-suspended in 200μL of PBS to determine the fluorescence content with a flow cytometer.

To evaluate the uptake of gold clusters in MCF-7 cells and SK-BR-3 cells, the uptake content of Au was determined by ICP-MS. Firstly, the MCF-7 cells and SK-BR-3 cells in the logarithmic growth phase were seeded in 24-well culture plate at 1.25×10^5 cells/well. After 24h, the GTSL-CYC, GTSL-CYC-HER2 and GTSL-CYC-HER2@NIR irradiation groups (3W/cm², 5 min/well) were added and incubated. At 2h, 4h, and 6h, the cells in holes were collected and lysed by 60 μL RIPA (containing 1mM PMSF). After complete lysis, the protein in the lysates was examined by BCA kit. Moreover, the Au content is determined by ICP-MS, and the Au content per unit protein is calculated to investigate the uptake behavior.

**Uptake inhibition experiment after HER2 receptor saturation**

To investigate the uptake mechanism of GTSL-CYC-HER2, the receptor inhibition experiment was carried out. The SK-BR-3 cells in the logarithmic growth phase were seeded in 24-well culture plate at 1.25×10^5 cells/well. The GTSL-CYC-HER2@NIR samples(3W/cm², 5 min/well) were added. In addition, the control group was firstly added with excess of HER2 antibody, and then the GTSL-CYC-HER2@NIR samples (3W/cm², 5 min/well) were added. At 2h, 4h, and 6h, the cells in holes were collected and lysed by 60 μL RIPA (containing 1mM PMSF). After complete lysis, the protein in the lysates was examined by BCA kit. Moreover, the Au content is determined by ICP-MS, and the Au content per unit protein is calculated to investigate the uptake behavior.

**In vivo study**

**Establishment of in-situ breast cancer-bearing mice model**

The SK-BR-3 cells in the logarithmic growth phase were collected and suspended in PBS at the density of 1×10^7/mL cell. Then 0.1ml of the solution was injected into the fourth pair of
mammary fat pads of Balb/c nude mice subcutaneously, to establish the in situ breast cancer model. All animal experiments were conducted in accordance with the guidelines of the Animal Ethics Committee of China Pharmaceutical University.

**The tumor targeting ability in vivo**

The breast cancer mice were randomly divided into three groups, 4 mice in each group, and were injected intravenously with Free-Dir, Dir@GTSL, and Dir@GTSL-HER2 at a dose of 1 mg/kg (CYC). Next, the images were recorded by *In vivo* imaging (Dir, excitation wavelength 745 nm, emission wavelength 800 nm) at 2h, 8h, and 24h after administration. At 24h, the nude mice were sacrificed, and the heart, liver, spleen, lung, kidney, brain and tumor were obtained and photographed by *In vivo* imaging to calculate the fluorescence intensity value, observing the targeting ability of the samples.

**The photothermal properties in vivo**

The breast cancer mice were randomly divided into three groups, 4 mice in each group, and were injected intravenously with saline, GTSL and GTSL-HER2 at a dose of 10mg/kg (Au) by tail vein. After 24h, the tumor tissue was irradiated with a 808nm laser (3W/cm2) for 5 minutes. An infrared thermal imager was used to monitor the temperature change of the tumor in real time.

**CT imaging studies in vivo**

The breast cancer mice were randomly divided into three groups, 4 mice in each group, and were injected intravenously with 0.2ml iohexol, GTSL and GTSL-HER2 at a dose of 10mg/kg (Au) by tail vein. The scans were performed on PET/CT before injection and 2h and 8h after injection. The instrument parameters were set as follows: tube voltage 80 kV, current intensity 500 μA, and single exposure time 250 ms. The tumor-bearing nude mice were sacrificed immediately after CT scan. After dissection, the tumor and main organ tissues (heart, liver, spleen, lung, kidney, brain, tumor) were obtained and weighed. Then the organs were digested using microwave digestion equipment to determine the gold content by ICP-MS. Finally, the percent cumulative amount of different preparations in different tissues %ID/g (percentage of injected dose/g) was calculated.

**The antitumor study in vivo**

The breast cancer mice were randomly divided into seven groups, 6 mice in each group, and were injected intravenously with the following samples, including normal saline group, light group (NIR group), free drug group (CYC), GTSL@NIR group, GTSLs-CYC@NIR group, GTSL-CYC-
HER2 group, GTSL-CYC-HER2@NIR group. The mice of each group was administered by tail vein injection at a dose of 10 mg/kg (at the base of CYC), and the amount of tail vein injection was 0.1 mL/10 g. The drug was firstly administered from the second week and then every 3 days for a total of 4 doses. The laser power of the laser irradiation group was set at 3W/cm² for 5 min after the administration. The tumor volume and weight of mice were monitored every 3 day to observe the antitumor effect. On the 14th day, the Balb/c nude mice were sacrificed. The tumor tissues were dissected and immersed in 4% paraformaldehyde solution, dehydrated, embedded, and sliced for further Hematoxylin-Eosin (H&E) Staining and TUNEL staining.

The safety study in vivo

The breast cancer mice were randomly divided into seven groups, 6 mice in each group, and were injected intravenously with the following samples, including normal saline group, light group (NIR group), free drug group (CYC), GTSL@NIR group, GTSL-CYC@NIR group, GTSL-CYC-HER2 group, GTSL-CYC-HER2@NIR group. The mice of each group was administered by tail vein injection at a dose of 10 mg/kg (at the base of CYC), and the amount of tail vein injection was 0.1 mL/10 g. The drug was firstly administered from the second week and then every 3 days for a total of 4 doses. On the 14th day, the Balb/c nude mice were sacrificed. In order to evaluate the damage to the tissue of the therapy, all the organs were obtained and immersed in 4% paraformaldehyde solution, dehydrated, embedded, and sliced for further Hematoxylin-Eosin (H&E) Staining.

Supplementary Information

Acknowledgement

The authors would like to thank China Pharmaceutical University and Nanjing Normal University for providing funding and facilities.

Disclosure

The author reports no conflicts of interest in this work.

Author Contributions
Yanan Li initiated, designed and wrote the literature. Wenting Song, Yumin Hu, Yun Xia and Zhen Li participated in carrying out experiments and analyzing the experiments data. Yan Shen and Yang Lu supervised and revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (NO. 81972892), and the Applied Technology Research and the Development Project of the Inner Mongolia Autonomous Region (2019GG035).

Declarations

Ethics approval and consent to participate

All animal experiments were approved by the Animal Ethics Committee of China Pharmaceutical University.

Consent for publication

All authors agreed to submit this manuscript.

Competing interests

The authors declare no competing interests.

Author details

a Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, 210009, P. R. China

b School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, P. R. China

c Laboratory of Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China

References

[1] J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebeho, D.M. Parkin, D. Forman, F. Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN
2012, Int J Cancer 136(5) (2015) E359-E386.
[2] A. Goldhirsch, R.D. Gelber, M.J. Piccart-Gebhart, E. de Azambuja, M. Procter, T.M. Suter, C. Jackisch, D. Cameron, H.A. Weber, D. Heinzeimann, L. Dal Lago, E. McFadden, M. Dowsett, M. Untch, L. Gianni, R. Bell, C.-H. Köhne, A. Vindevoghel, M. Andersson, A.M. Brun, D. Otero-Reyes, S. Song, I. Smith, B. Leyland-Jones, J. Baselga, 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial, Lancet 382(9897) (2013) 1021-1028.
[3] N.S. Abadeer, C.J. Murphy, Recent Progress in Cancer Thermal Therapy Using Gold Nanoparticles, J. Phys. Chem. C 120(9) (2016) 4691-4716.
[4] M. Hu, J. Chen, Z.-Y. Li, L. Au, G.V. Hartland, X. Li, M. Marquez, Y. Xia, Gold nanostructures: engineering their plasmonic properties for biomedical applications, Chem Soc Rev 35(11) (2006) 1084-1094.
[5] A. Abbasi, K. Park, A. Bose, G.D. Bothun, Near-Infrared Responsive Gold-Layersome Nanoshells, Langmuir 33(21) (2017) 5321-5327.
[6] H.-W. An, L.-L. Li, Y. Wang, Z. Wang, D. Hou, Y.-X. Lin, S.-L. Qiao, M.-D. Wang, C. Yang, Y. Cong, Y. Ma, X.-X. Zhao, Q. Cai, W.-T. Chen, C.-Q. Lu, W. Xu, H. Wang, Y. Zhao, A tumour-selective cascade activatable self-detained system for drug delivery and cancer imaging, Nat Commun 10(1) (2019) 4861.
[7] T. Jiang, B. Zhang, S. Shen, Y. Tuo, Z. Luo, Y. Hu, Z. Pang, X. Jiang, Tumor Microenvironment Modulation by Cyclopamine Improved Photothermal Therapy of Biomimetic Gold Nanorods for Pancreatic Ductal Adenocarcinomas, ACS Appl Mater Interfaces 9(37) (2017) 31497-31508.
[8] I.A. Khawar, J.H. Kim, H.-J. Kuh, Improving drug delivery to solid tumors: priming the tumor microenvironment, J Control Release 201 (2015) 78-89.
[9] K.C. Valkenburg, A.E. de Groot, K.J. Pienta, Targeting the tumour stroma to improve cancer therapy, Nat Rev Clin Oncol 15(6) (2018) 366-381.
[10] B. Zhang, T. Jiang, S. Shen, X. She, Y. Tuo, Y. Hu, Z. Pang, X. Jiang, Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer, Biomaterials 103 (2016) 12-21.
[11] P. Heretsch, L. Tzagkaroulaki, A. Giannis, Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives, Angew Chem Int Ed Engl 49(20) (2010) 3418-3427.
[12] B. Zhang, H. Wang, T. Jiang, K. Jin, Z. Luo, W. Shi, H. Mei, H. Wang, Y. Hu, Z. Pang, X. Jiang, Cyclopamine treatment disrupts extracellular matrix and alleviates solid stress to improve nanomedicine delivery for pancreatic cancer, J Drug Target 26(10) (2018) 913-919.
[13] J. Shi, P.W. Kantoff, R. Wooster, O.C. Farokhzad, Cancer nanomedicine: progress, challenges and opportunities, Nat Rev Cancer 17(1) (2017) 20-37.
[14] N. Yu, L. Huang, Y. Zhou, T. Xue, Z. Chen, G. Han, Near-Infrared-Light Activatable Nanoparticles for Deep-Tissue-Penetrating Wireless Optogenetics, Adv Healthc Mater 8(6) (2019) e1801132.
[15] T. Chen, D. Cen, Z. Ren, Y. Wang, X. Cai, J. Huang, L. Di Silvio, X. Li, G. Han, Bismuth embedded silica nanoparticles loaded with autophagy suppressant to promote photothermal therapy, Biomaterials 221 (2019) 119419.
[16] M. Khaleedian, M.S. Nourbakhsh, R. Saber, H. Hashemzadeh, M.H. Darvishi, Preparation and Evaluation of Doxorubicin-Loaded PLA-PEG-FA Copolymer Containing Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Cancer Treatment: Combination Therapy with Hyperthermia and Chemotherapy, Int J Nanomedicine 15 (2020) 6167-6182.
[17] S. Stapleton, M. Dunne, M. Milosevic, C.W. Tran, M.J. Gold, A. Vedadi, T.D. McKee, P.S. Ohashi, C. Allen, D.A. Jaffray, Radiation and Heat Improve the Delivery and Efficacy of Nanotherapeutics by
[18] T. Wang, L. Wang, X. Li, X. Hu, Y. Han, Y. Luo, Z. Wang, Q. Li, A. Aldalbahi, L. Wang, S. Song, C. Fan, Y. Zhao, M. Wang, N. Chen, Size-Dependent Regulation of Intracellular Trafficking of Polystyrene Nanoparticle-Based Drug-Delivery Systems, ACS Appl Mater Interfaces 9(22) (2017) 18619-18625.

[19] Y. Guo, E. Terazzi, R. Seemann, J.B. Fleury, V.A. Baulin, Direct proof of spontaneous translocation of lipid-covered hydrophobic nanoparticles through a phospholipid bilayer, Sci Adv 2(11) (2016) e1600261.

[20] E. Samuelsson, H. Shen, E. Blanco, M. Ferrari, J. Wolfram, Contribution of Kupffer cells to liposome accumulation in the liver, Colloids Surf B Biointerfaces 158 (2017) 356-362.

[21] Y.-S. Kim, J.-H. Cho, S.G. Ansari, Immobilization of avidin on the functionalized carbon nanotubes, Synthetic Metals 156(14/15) (2006) 938-943.

[22] T. Yang, M.-K. Choi, F.-D. Cui, J.S. Kim, S.-J. Chung, C.-K. Shim, D.-D. Kim, Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome, J Control Release 120(3) (2007) 169-177.

[23] D. Bartczak, A.G. Kanaras, Preparation of peptide-functionalized gold nanoparticles using one pot EDC/Sulfo-NHS coupling, Langmuir: The ACS Journal of Surfaces and Colloids 27(16) (2011) 10119-10123.

[24] X. Zhu, W. Feng, J. Chang, Y.-W. Tan, J. Li, M. Chen, Y. Sun, F. Li, Temperature-feedback upconversion nanocomposite for accurate photothermal therapy at facile temperature, Nat Commun 7 (2016) 10437.

[25] T.-C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev 58(3) (2006) 621-681.
